XML 128 R108.htm IDEA: XBRL DOCUMENT

Long-Lived Assets

12 Months Ended

Dec. 31, 2022

(6)Long-Lived Assets

Property and Equipment

Property and equipment as of December 31 consists of the following:


	Useful Life
	(Years)	2022		2021
Machinery and equipment	5 – 7	$	2,795	$	2,031
Computers and software	2		602		672
Furniture	5		475		448
Leasehold improvements	5		772		783
Other property	7		12		12
			4,656		3,946
Less accumulated depreciation			(2,425)		(2,149)
		$	2,231	$	1,797

Depreciation expense for property and equipment for the years ended December 31, 2022 and 2021, was $276 and $361, respectively. The Company did not recognize any impairment losses for the years ended December 31, 2022 and 2021, other than a loss on disposal of $310 in 2022.

Intangible Assets

Intangible assets consist entirely of patent costs that provide the Company with rights, titles, and interests in the development of certain processes, discoveries, and inventions with the right to commercialize that are probable of future economic benefits. Patent costs associated with pharmaceutical intellectual property are expensed as incurred as future economic benefits are not deemed to be probable. Intangible assets are recorded at cost and are amortized over the estimated life of the patents, based on the approval and expiration dates applicable to each patent — typically 20 years — on a straight-line basis. Amortization expense related to intellectual property for 2022 and 2021 was $122 and $103, respectively. We did not record any impairment losses in 2022 or 2021. The estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal years is as follows:


2023		65
2024		65
2025		65
2026		65
2027		65
Thereafter		477
	$	802